Haemophilus influenzae cDNA and Antigen

Haemophilus influenzae is a gram-negative bacterium that commonly colonizes the upper respiratory tract of humans. While most strains are non-pathogenic, some can cause a range of serious infections, particularly in young children and immunocompromised individuals. Pneumonia, meningitis, and sepsis are among the most severe illnesses caused by H. influenzae, and can be life-threatening if not promptly diagnosed and treated.

Protective surface antigen D15 is a protein found on the surface of H. influenzae that has been shown to be a promising target for vaccine development. This protein is involved in the adhesion and invasion of the bacterium into host cells, and antibodies against it can prevent or reduce the severity of infection. Vaccines targeting D15 have been shown to be effective in animal models, and clinical trials are underway to evaluate their safety and efficacy in humans.

Uncharacterized protein 60 kDa chaperonin Cpn60, also known as GroEL, is another protein that has been identified as a potential target for vaccine development against H. influenzae. This protein is a highly conserved chaperonin that is essential for the proper folding and function of other proteins in the bacterium. Antibodies against Cpn60 have been shown to have bactericidal activity against H. influenzae, and vaccines targeting this protein have shown promise in animal studies.

In addition to their potential use in vaccine development, these antigens may also have diagnostic and therapeutic applications. For example, antibodies against D15 and Cpn60 could be used in diagnostic tests to detect H. influenzae infections, or in passive immunization strategies to treat or prevent infections. However, further research is needed to fully understand the role of these antigens in the pathogenesis of H. influenzae, and to develop effective diagnostic and therapeutic approaches based on them.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Haemophilus influenzae cDNA and recombinant antigen can be used to detect and diagnose infections caused by H. influenzae. The cDNA can be used in PCR-based assays to identify the presence of H. influenzae in a sample. Recombinant antigen can be used to detect the presence of antibodies in the serum of an infected individual. Both of these methods can be used to diagnose H. influenzae infections in humans and animals. They can also be used to monitor the effectiveness of treatments for H. influenzae infections. Additionally, cDNA and recombinant antigen can be used to study the genetics and pathogenesis of H. influenzae. They can also be used to develop new vaccines and treatments for H. influenzae infections.